ERBB2 and neutropenia: The most common AEs with chidamide were thrombocytopenia, leucopenia, neutropenia, and anemia.<h4>Conclusion</h4>This study provided real-world data for the use of chidamide in patients with HoR-positive and HER2-negative MBC.